Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - sevoflurane, quantity: 1 ml/ml - inhalation - excipient ingredients: - piramal sevoflurane may be used for induction and maintenance of general anaesthesia in adult and paediatric patients undergoing surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

piramal critical care pty ltd - desflurane, quantity: 1 ml/ml - inhalation - excipient ingredients: - piramal desflurane is indicated as an inhalation agent for maintenance of anaesthesia. desflurane is not recommended for mask induction of anaesthesia because of a high incidence of moderate to severe upper airway adverse events.

New Zealand - English - Medsafe (Medicines Safety Authority)

device technologies new zealand - sevoflurane 100%{vol} - volatile liquid for inhalation - 100% v/v - active: sevoflurane 100%{vol} - piramal sevoflurane may be used for the induction and maintenance of general anaesthesia in adult and paediatric patients undergoing surgery.

European Union - English - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuscular blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Israel - English - Ministry of Health

medison pharma ltd - burosumab - solution for injection - burosumab 10 mg / 1 ml - burosumab - crysvita is indicated for the treatment of x-linked hypophosphatemia (xlh) in adult and paediatric patients 6 months of age and oldertumor-induced osteomalaciacrysvita is indicated for the treatment of fgf23‐related hypophosphatemia in tumor‐induced osteomalacia (tio) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

Israel - English - Ministry of Health

medison pharma ltd - burosumab - solution for injection - burosumab 20 mg / 1 ml - burosumab - crysvita is indicated for the treatment of x-linked hypophosphatemia (xlh) in adult and paediatric patients 6 months of age and oldertumor-induced osteomalaciacrysvita is indicated for the treatment of fgf23‐related hypophosphatemia in tumor‐induced osteomalacia (tio) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

Israel - English - Ministry of Health

medison pharma ltd - burosumab - solution for injection - burosumab 30 mg / 1 ml - burosumab - crysvita is indicated for the treatment of x-linked hypophosphatemia (xlh) in adult and paediatric patients 6 months of age and oldertumor-induced osteomalaciacrysvita is indicated for the treatment of fgf23‐related hypophosphatemia in tumor‐induced osteomalacia (tio) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

Kenya - English - Pharmacy and Poisons Board

piramal enterprises limited piramal ananta, agastya corporate park, opp. fire - isoflurane - inhalation vapour - isoflurane 250ml - general anesthetics: halogenatedhydrocarbons

Malta - English - Medicines Authority

piramal critical care b.v. rouboslaan 32 (ground floor), 2252 tr, voorschoten, netherlands - isoflurane - inhalation vapour, liquid - isoflurane 100 % - anesthetics

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - norethisterone - tablets - 350 microgram - progestogens